Read by QxMD icon Read

Chinese Clinical Oncology

Rick L Haas, Michiel A J van de Sande
No abstract text is available yet for this article.
January 24, 2019: Chinese Clinical Oncology
Doaa Shalabi, Anna Bistline, Onder Alpdogan, Saritha Kartan, Anjali Mishra, Pierluigi Porcu, Neda Nikbakht
Mycosis fungoides (MF) and Sézary syndrome (SS) are two well-characterized skin limited and leukemic subtypes of cutaneous T-cell lymphoma (CTCL), respectively. Progressive global immune dysfunction and a multitude of specific immunological abnormalities have long been recognized as features of MF and SS. Therefore, a variety of immune-based therapies have been explored and used in the clinic for decades in the attempt to restore the immune imbalance in these malignancies. With recent advances in the development of novel immunotherapies in cancer treatment, new treatment modalities have emerged to complement the existing repertoire...
January 9, 2019: Chinese Clinical Oncology
Saritha Kartan, William T Johnson, Kelsey Sokol, Onder Alpdogan, Alejandro A Gru, Neda Nikbakht, Pierluigi Porcu
Primary cutaneous CD30+ T cell lymphoproliferative disorders (pcCD30+ T cell LPDs) are a spectrum of pre-malignant to frankly neoplastic lymphoproliferations that comprise lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions. Although the atypical T cells that are the hallmark of these disorders share the expression of CD30, as the identifying marker, the clinical presentation, histological features and clinical course are vastly different. Furthermore, histopathologic features of pcCD30+ T cell LPDs may overlap with other cutaneous and systemic lymphomas...
January 9, 2019: Chinese Clinical Oncology
Alhadi Almangush, Tuula Salo
No abstract text is available yet for this article.
January 8, 2019: Chinese Clinical Oncology
Junichi Shindoh
No abstract text is available yet for this article.
January 2, 2019: Chinese Clinical Oncology
Sabrina Daniela da Silva, Luiz Paulo Kowalski
No abstract text is available yet for this article.
December 4, 2018: Chinese Clinical Oncology
Cristina Cristofoletti, Maria Grazia Narducci, Giandomenico Russo
Sezary syndrome (SS) is a primary cutaneous T-cell lymphoma (CTCL) characterized by erythroderma, lymphadenopathy and leukemic involvement of the peripheral blood. The high relapse rates and a poor prognosis complicate its clinical course and treatment. The phenotypic characterization and genomic/transcriptomic approaches revealed high heterogeneity of Sezary cells, identifying a wide spectrum of biomarkers implicated in the development of this lymphoma. In this context, we discuss the major malignancy-related biomarkers reported in the literature for the diagnosis, prognosis and staging of SS...
November 28, 2018: Chinese Clinical Oncology
Marie-Louise Lovgren, Julia J Scarisbrick
Mycosis fungoides (MF) represents the majority of the primary cutaneous T-cell lymphomas (CTCL). Most have early stage MF with localised patches and plaques, which has a favourable survival outcome, but nearly a quarter progress to late stage with tumours, erythroderma, and systemic involvement. Management is based on stage directed treatment with early stage MF (IA-IIA) using skin directed therapies (SDTs), including topical corticosteroids (TCS), chlormethine or retinoids, phototherapy, and radiotherapy (localised or total skin electron beam therapy)...
November 28, 2018: Chinese Clinical Oncology
Brad Li
No abstract text is available yet for this article.
December 2018: Chinese Clinical Oncology
Alexandr O Ivantsov
There is only a few of studies devoted to evaluation of pathologic response of ovarian cancer (OC) to neoadjuvant chemotherapy (NACT). Pathologic complete responses (pCR), which are characterized by the lack of viable tumor cells in surgical specimens, are rarely observed in ovarian carcinomas. Multiple reports demonstrate that pCR is associated with evidently improved disease outcomes. Recommendations of the International Collaboration on Cancer Reporting suggest to use recently developed Chemotherapy Response Scoring (CRS) system, which is based on the pathological analysis of surgically removed omental masses...
December 2018: Chinese Clinical Oncology
Jae Hyun Cho, Seik Kim, Yong Sang Song
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancy and is the seventh most common cancer among women worldwide. The primary debulking surgery (PDS) followed by adjuvant chemotherapy (ACT) is a standard treatment of advanced EOC. However, there are still several limitations, such as high recurrence rate and subsequent chemoresistance. To date, many studies have reported that neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) shows non-inferior survival outcome and is associated with less postoperative morbidity compared with PDS...
December 2018: Chinese Clinical Oncology
Tatiana V Gorodnova, Anna P Sokolenko, Ekatherina Kuligina, Igor V Berlev, Evgeny N Imyanitov
Epithelial ovarian cancer (EOC) is a common malignant disease, which remains asymptomatic for a prolonged period of time and is usually diagnosed at advanced stages. Cytoreductive surgery is a backbone of EOC treatment. Wherever possible, EOC patients are subjected to primary debulking surgery (PDS) with the aim to remove all visible tumor lumps. Some patients cannot undergo PDS due to extensive disease spread and/or high risk of perioperative morbidity, therefore they are subjected to neoadjuvant chemotherapy (NACT) before the surgery...
December 2018: Chinese Clinical Oncology
Evgeny N Imyanitov, Grigoriy A Yanus
Neoadjuvant therapy (NAT) is widely utilized in the routine management of cancer patients and various clinical trials for the treatment of breast, ovarian, rectal, esophageal, head and neck, lung, prostate and many other cancer types. There is a number of potential benefits of applying systemic treatment before the operation. NAT may significantly reduce the tumor burden thus allowing less traumatic surgery. NAT is often considered as personalized in vivo drug sensitivity test, as it allows rapid evaluation of tumor response to a given therapy and consequent adjustment of further treatment planning...
December 2018: Chinese Clinical Oncology
Evgeny N Imyanitov
No abstract text is available yet for this article.
December 2018: Chinese Clinical Oncology
Vishal Jindal
Prostate cancer was the first cancer in which immunotherapy vaccine was approved by FDA in 2010 named Sipuleucel-T. No new immunotherapies have been approved since, as phase 3 trials didn't show any improvement in overall survival (OS) especially with immune checkpoint inhibitors. Currently tremendous amount of research is going on, in studying microenvironment of prostate cancer, finding new targets and biomarkers, and trying different combination therapies. Some of the new targets explored are VISTA and PARP inhibitors...
December 2018: Chinese Clinical Oncology
Shamir Geller, Patricia L Myskowski, Melissa Pulitzer, Steven M Horwitz, Alison J Moskowitz
The vast majority of cutaneous T-cell lymphomas (CTCL) are encompassed by mycosis fungoides and CD30+ lymphoproliferative disorder (LPD), however rare distinct CTCLs have been defined. The current edition of the World Health Organization (WHO) includes 12 CTCL subtypes with discrete diagnosable clinical, histologic and phenotypic features. The rarest subtypes, i.e. those that comprise <1% to 2%, include indolent entities, such as primary cutaneous CD4+ small/medium T-cell LPD (SMPTC-LPD), primary cutaneous acral CD8+ T-cell lymphoma (acral CD8+ TCL) and subcutaneous panniculitis-like TCL (SPTCL) and aggressive entities, such as primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (CD8+ PCAETL) and primary cutaneous gamma /delta T-cell lymphoma (PCGDTCL)...
November 21, 2018: Chinese Clinical Oncology
Tara Jennings, Robert Duffy, Ashley Gochoco, Kelly Knoblauch, Wenyin Shi, S Onder Alpdogan, Pierluigi Porcu, Maria Werner-Wasik, Joya Sahu
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma within the general population. Low dose total skin electron beam therapy (TSEBT) and topical nitrogen mustard (Valchlor) are two treatment modalities that have been proven to be efficacious in the treatment of MF. While each have been studied independently in various clinical trials, the use of Valchlor as maintenance therapy after completion of low dose TSEBT is rarely implemented due to the lack of evidence in the literature. The Jefferson multidisciplinary cutaneous lymphoma clinic has found great success with this combination of treatment and it was the goal of the authors to provide further evidence to its efficacy...
November 14, 2018: Chinese Clinical Oncology
Tianhong Li, Weijie Ma, Eddie C Tian
No abstract text is available yet for this article.
November 9, 2018: Chinese Clinical Oncology
Salvatore Lorenzo Renne
No abstract text is available yet for this article.
November 9, 2018: Chinese Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"